TransMedics® Announced Final Results of The PROCEED II Heart FDA Pivotal Trial at ISHLT

TransMedics® Announced Final Results of The PROCEED II Heart FDA Pivotal Trial at ISHLT

April 14, 2014

ANDOVER, Mass., April 14, 2014 /PRNewswire/ -- The PROCEED II heart transplant Food and Drug Administration (FDA) pivotal trial results using the Organ Care System (OCS™) –Heart platform were announced on Saturday, April 12, 2014 at the International Society for Heart and Lung Transplantation (ISHLT) 34th Annual Meeting and Scientific Sessions in

Oasys Water Honored as One of Bloomberg’s 2014 New Energy Pioneers at BNEF’s Future of Energy Summit

Oasys Water Honored as One of Bloomberg’s 2014 New Energy Pioneers at BNEF’s Future of Energy Summit

April 8, 2014

Recognized for its Ability to Change the Energy Landscape Worldwide 

Oasys Water Named 2014 Water Technology Company of the Year

Oasys Water Named 2014 Water Technology Company of the Year

April 8, 2014

Company’s Innovative Forward Osmosis Technology Recognized for its Significant Contributions to the Field of Water Technology

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

BIND Therapeutics Presents Clinical Data Highlighting Unique Attributes of Lead Cancer Drug Candidate, BIND-014, at AACR 2014 Annual Meeting

April 7, 2014

Results Demonstrated Increased Dose Intensity of Weekly Dosing vs. Every Three Week Dosing Schedule of BIND-014 and Utility of PSMA as a Biomarker for Patient Selection

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

Agios Announces Initial Phase 1 Data Demonstrating Clinical Activity of AG-221, First-in-Class Inhibitor of IDH2 Mutations, in Patients with Advanced Blood Cancers

April 6, 2014

- Significant Clinical Responses and Reduction of 2HG Biomarker in Early Cohorts -- Data Presented at AACR Corroborate Company’s Precision Medicine Approach in Targeting Cancer Metabolism; Company to Host Investor Webcast on April 6 -

T2 Biosystems Appoints Michael Pfaller, MD, Chief Medical Officer

T2 Biosystems Appoints Michael Pfaller, MD, Chief Medical Officer

April 3, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)--T2 Biosystems, a company developing direct detection products designed to enable superior diagnostics, today announced that Michael Pfaller, MD, has joined the company as Chief Medical Officer. Dr. Pfaller will oversee medical affairs including infectious disease and hemostasis advisory boards, and clinical research and physician education programs associated with the anticipated launch of the Company’s flagship diagnostic test, T2Candida, upon receipt of marketing authorization from the U.S. Food and Drug Administration (FDA).

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

BG Medicine, Inc. Announces Proposed Public Offering of Common Stock

April 2, 2014

WALTHAM, Mass., April 2, 2014 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering.

Concert Pharmaceuticals Reports Year End 2013 Financial Results

Concert Pharmaceuticals Reports Year End 2013 Financial Results

March 31, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the year ended December 31, 2013 and provided an update on corporate activities.

Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

Seres Health to Present at 21st Annual BioCentury Future Leaders in the Biotech Industry Conference

March 25, 2014

CAMBRIDGE, Mass., March 25, 2014 /PRNewswire/ -- Seres Health, a clinical-stage therapeutics company developing novel products to treat a host of disease conditions based on scientific findings related to the human microbiome, today announced that CEO and Co-founder Dr.

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

BIND Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results

March 25, 2014

 Management to host conference call today at 8:30 am ET

CAMBRIDGE, Mass., Mar 25, 2014 (BUSINESS WIRE) -- BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.